The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Viral Vectors Gene Therapy Market Research Report 2025
Synopsis
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
The global Viral Vectors Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Viral Vectors Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors Gene Therapy.
Report Scope
The Viral Vectors Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
Segment by Type
Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Segment by Application
In Vivo
Ex Vivo
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Viruses have evolved to become highly efficient at nucleic acid delivery to specific cell types while avoiding immunosurveillance by an infected host. These properties make viruses attractive gene-delivery vehicles, or vectors, for gene therapy. Several types of viruses, including retrovirus, adenovirus, adeno-associated virus (AAV), and herpes simplex virus, have been modified in the laboratory for use in gene therapy applications. Because these vector systems have unique advantages and limitations, each has applications for which it is best suited. Retroviral vectors can permanently integrate into the genome of the infected cell, but require mitotic cell division for transduction. Adenoviral vectors can efficiently deliver genes to a wide variety of dividing and nondividing cell types, but immune elimination of infected cells often limits gene expression in vivo.
The global Viral Vectors Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Viral Vectors Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Viral Vectors Gene Therapy.
Report Scope
The Viral Vectors Gene Therapy market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Viral Vectors Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Viral Vectors Gene Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
Novartis
Orchard Therapeutics
Spark Therapeutics
Agc Biologics
Anges
Bluebird Bio
Jazz Pharmaceuticals
Dynavax Technologies
Biogen
Sarepta Therapeutics
Gilead Sciences
Segment by Type
Retro Viral Vectors
Adeno-associated Virus Vectors
Other Viral Vectors
Segment by Application
In Vivo
Ex Vivo
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vectors Gene Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vectors Gene Therapy Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Retro Viral Vectors
1.2.3 Adeno-associated Virus Vectors
1.2.4 Other Viral Vectors
1.3 Market by Application
1.3.1 Global Viral Vectors Gene Therapy Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 In Vivo
1.3.3 Ex Vivo
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vectors Gene Therapy Market Perspective (2019-2030)
2.2 Viral Vectors Gene Therapy Growth Trends by Region
2.2.1 Global Viral Vectors Gene Therapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Viral Vectors Gene Therapy Historic Market Size by Region (2019-2024)
2.2.3 Viral Vectors Gene Therapy Forecasted Market Size by Region (2025-2030)
2.3 Viral Vectors Gene Therapy Market Dynamics
2.3.1 Viral Vectors Gene Therapy Industry Trends
2.3.2 Viral Vectors Gene Therapy Market Drivers
2.3.3 Viral Vectors Gene Therapy Market Challenges
2.3.4 Viral Vectors Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Viral Vectors Gene Therapy Players by Revenue
3.1.1 Global Top Viral Vectors Gene Therapy Players by Revenue (2019-2024)
3.1.2 Global Viral Vectors Gene Therapy Revenue Market Share by Players (2019-2024)
3.2 Global Viral Vectors Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Viral Vectors Gene Therapy Revenue
3.4 Global Viral Vectors Gene Therapy Market Concentration Ratio
3.4.1 Global Viral Vectors Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vectors Gene Therapy Revenue in 2023
3.5 Viral Vectors Gene Therapy Key Players Head office and Area Served
3.6 Key Players Viral Vectors Gene Therapy Product Solution and Service
3.7 Date of Enter into Viral Vectors Gene Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vectors Gene Therapy Breakdown Data by Type
4.1 Global Viral Vectors Gene Therapy Historic Market Size by Type (2019-2024)
4.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2025-2030)
5 Viral Vectors Gene Therapy Breakdown Data by Application
5.1 Global Viral Vectors Gene Therapy Historic Market Size by Application (2019-2024)
5.2 Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Viral Vectors Gene Therapy Market Size (2019-2030)
6.2 North America Viral Vectors Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Viral Vectors Gene Therapy Market Size by Country (2019-2024)
6.4 North America Viral Vectors Gene Therapy Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Viral Vectors Gene Therapy Market Size (2019-2030)
7.2 Europe Viral Vectors Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Viral Vectors Gene Therapy Market Size by Country (2019-2024)
7.4 Europe Viral Vectors Gene Therapy Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Viral Vectors Gene Therapy Market Size (2019-2030)
8.2 Asia-Pacific Viral Vectors Gene Therapy Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2019-2024)
8.4 Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Viral Vectors Gene Therapy Market Size (2019-2030)
9.2 Latin America Viral Vectors Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Viral Vectors Gene Therapy Market Size by Country (2019-2024)
9.4 Latin America Viral Vectors Gene Therapy Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Viral Vectors Gene Therapy Market Size (2019-2030)
10.2 Middle East & Africa Viral Vectors Gene Therapy Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2019-2024)
10.4 Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Viral Vectors Gene Therapy Introduction
11.1.4 Amgen Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Viral Vectors Gene Therapy Introduction
11.2.4 Novartis Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Orchard Therapeutics
11.3.1 Orchard Therapeutics Company Detail
11.3.2 Orchard Therapeutics Business Overview
11.3.3 Orchard Therapeutics Viral Vectors Gene Therapy Introduction
11.3.4 Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.3.5 Orchard Therapeutics Recent Development
11.4 Spark Therapeutics
11.4.1 Spark Therapeutics Company Detail
11.4.2 Spark Therapeutics Business Overview
11.4.3 Spark Therapeutics Viral Vectors Gene Therapy Introduction
11.4.4 Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.4.5 Spark Therapeutics Recent Development
11.5 Agc Biologics
11.5.1 Agc Biologics Company Detail
11.5.2 Agc Biologics Business Overview
11.5.3 Agc Biologics Viral Vectors Gene Therapy Introduction
11.5.4 Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.5.5 Agc Biologics Recent Development
11.6 Anges
11.6.1 Anges Company Detail
11.6.2 Anges Business Overview
11.6.3 Anges Viral Vectors Gene Therapy Introduction
11.6.4 Anges Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.6.5 Anges Recent Development
11.7 Bluebird Bio
11.7.1 Bluebird Bio Company Detail
11.7.2 Bluebird Bio Business Overview
11.7.3 Bluebird Bio Viral Vectors Gene Therapy Introduction
11.7.4 Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.7.5 Bluebird Bio Recent Development
11.8 Jazz Pharmaceuticals
11.8.1 Jazz Pharmaceuticals Company Detail
11.8.2 Jazz Pharmaceuticals Business Overview
11.8.3 Jazz Pharmaceuticals Viral Vectors Gene Therapy Introduction
11.8.4 Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.8.5 Jazz Pharmaceuticals Recent Development
11.9 Dynavax Technologies
11.9.1 Dynavax Technologies Company Detail
11.9.2 Dynavax Technologies Business Overview
11.9.3 Dynavax Technologies Viral Vectors Gene Therapy Introduction
11.9.4 Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.9.5 Dynavax Technologies Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Viral Vectors Gene Therapy Introduction
11.10.4 Biogen Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.10.5 Biogen Recent Development
11.11 Sarepta Therapeutics
11.11.1 Sarepta Therapeutics Company Detail
11.11.2 Sarepta Therapeutics Business Overview
11.11.3 Sarepta Therapeutics Viral Vectors Gene Therapy Introduction
11.11.4 Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.11.5 Sarepta Therapeutics Recent Development
11.12 Gilead Sciences
11.12.1 Gilead Sciences Company Detail
11.12.2 Gilead Sciences Business Overview
11.12.3 Gilead Sciences Viral Vectors Gene Therapy Introduction
11.12.4 Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2019-2024)
11.12.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Viral Vectors Gene Therapy Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Retro Viral Vectors
Table 3. Key Players of Adeno-associated Virus Vectors
Table 4. Key Players of Other Viral Vectors
Table 5. Global Viral Vectors Gene Therapy Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Viral Vectors Gene Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Viral Vectors Gene Therapy Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Viral Vectors Gene Therapy Market Share by Region (2019-2024)
Table 9. Global Viral Vectors Gene Therapy Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Viral Vectors Gene Therapy Market Share by Region (2025-2030)
Table 11. Viral Vectors Gene Therapy Market Trends
Table 12. Viral Vectors Gene Therapy Market Drivers
Table 13. Viral Vectors Gene Therapy Market Challenges
Table 14. Viral Vectors Gene Therapy Market Restraints
Table 15. Global Viral Vectors Gene Therapy Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Viral Vectors Gene Therapy Market Share by Players (2019-2024)
Table 17. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2023)
Table 18. Ranking of Global Top Viral Vectors Gene Therapy Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Viral Vectors Gene Therapy Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Viral Vectors Gene Therapy Product Solution and Service
Table 22. Date of Enter into Viral Vectors Gene Therapy Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Viral Vectors Gene Therapy Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2019-2024)
Table 26. Global Viral Vectors Gene Therapy Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Viral Vectors Gene Therapy Revenue Market Share by Type (2025-2030)
Table 28. Global Viral Vectors Gene Therapy Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2019-2024)
Table 30. Global Viral Vectors Gene Therapy Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Viral Vectors Gene Therapy Revenue Market Share by Application (2025-2030)
Table 32. North America Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Viral Vectors Gene Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Viral Vectors Gene Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Viral Vectors Gene Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Viral Vectors Gene Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Viral Vectors Gene Therapy Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Viral Vectors Gene Therapy Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Viral Vectors Gene Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Viral Vectors Gene Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Viral Vectors Gene Therapy Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Viral Vectors Gene Therapy Market Size by Country (2025-2030) & (US$ Million)
Table 47. Amgen Company Detail
Table 48. Amgen Business Overview
Table 49. Amgen Viral Vectors Gene Therapy Product
Table 50. Amgen Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 51. Amgen Recent Development
Table 52. Novartis Company Detail
Table 53. Novartis Business Overview
Table 54. Novartis Viral Vectors Gene Therapy Product
Table 55. Novartis Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Orchard Therapeutics Company Detail
Table 58. Orchard Therapeutics Business Overview
Table 59. Orchard Therapeutics Viral Vectors Gene Therapy Product
Table 60. Orchard Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 61. Orchard Therapeutics Recent Development
Table 62. Spark Therapeutics Company Detail
Table 63. Spark Therapeutics Business Overview
Table 64. Spark Therapeutics Viral Vectors Gene Therapy Product
Table 65. Spark Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 66. Spark Therapeutics Recent Development
Table 67. Agc Biologics Company Detail
Table 68. Agc Biologics Business Overview
Table 69. Agc Biologics Viral Vectors Gene Therapy Product
Table 70. Agc Biologics Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 71. Agc Biologics Recent Development
Table 72. Anges Company Detail
Table 73. Anges Business Overview
Table 74. Anges Viral Vectors Gene Therapy Product
Table 75. Anges Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 76. Anges Recent Development
Table 77. Bluebird Bio Company Detail
Table 78. Bluebird Bio Business Overview
Table 79. Bluebird Bio Viral Vectors Gene Therapy Product
Table 80. Bluebird Bio Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 81. Bluebird Bio Recent Development
Table 82. Jazz Pharmaceuticals Company Detail
Table 83. Jazz Pharmaceuticals Business Overview
Table 84. Jazz Pharmaceuticals Viral Vectors Gene Therapy Product
Table 85. Jazz Pharmaceuticals Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 86. Jazz Pharmaceuticals Recent Development
Table 87. Dynavax Technologies Company Detail
Table 88. Dynavax Technologies Business Overview
Table 89. Dynavax Technologies Viral Vectors Gene Therapy Product
Table 90. Dynavax Technologies Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 91. Dynavax Technologies Recent Development
Table 92. Biogen Company Detail
Table 93. Biogen Business Overview
Table 94. Biogen Viral Vectors Gene Therapy Product
Table 95. Biogen Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 96. Biogen Recent Development
Table 97. Sarepta Therapeutics Company Detail
Table 98. Sarepta Therapeutics Business Overview
Table 99. Sarepta Therapeutics Viral Vectors Gene Therapy Product
Table 100. Sarepta Therapeutics Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 101. Sarepta Therapeutics Recent Development
Table 102. Gilead Sciences Company Detail
Table 103. Gilead Sciences Business Overview
Table 104. Gilead Sciences Viral Vectors Gene Therapy Product
Table 105. Gilead Sciences Revenue in Viral Vectors Gene Therapy Business (2019-2024) & (US$ Million)
Table 106. Gilead Sciences Recent Development
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Viral Vectors Gene Therapy Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Viral Vectors Gene Therapy Market Share by Type: 2023 VS 2030
Figure 3. Retro Viral Vectors Features
Figure 4. Adeno-associated Virus Vectors Features
Figure 5. Other Viral Vectors Features
Figure 6. Global Viral Vectors Gene Therapy Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Viral Vectors Gene Therapy Market Share by Application: 2023 VS 2030
Figure 8. In Vivo Case Studies
Figure 9. Ex Vivo Case Studies
Figure 10. Viral Vectors Gene Therapy Report Years Considered
Figure 11. Global Viral Vectors Gene Therapy Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Viral Vectors Gene Therapy Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Viral Vectors Gene Therapy Market Share by Region: 2023 VS 2030
Figure 14. Global Viral Vectors Gene Therapy Market Share by Players in 2023
Figure 15. Global Top Viral Vectors Gene Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Viral Vectors Gene Therapy as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Viral Vectors Gene Therapy Revenue in 2023
Figure 17. North America Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Viral Vectors Gene Therapy Market Share by Country (2019-2030)
Figure 19. United States Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Viral Vectors Gene Therapy Market Share by Country (2019-2030)
Figure 23. Germany Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Viral Vectors Gene Therapy Market Share by Region (2019-2030)
Figure 31. China Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Viral Vectors Gene Therapy Market Share by Country (2019-2030)
Figure 39. Mexico Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Viral Vectors Gene Therapy Market Share by Country (2019-2030)
Figure 43. Turkey Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Viral Vectors Gene Therapy Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Amgen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 46. Novartis Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 47. Orchard Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 48. Spark Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 49. Agc Biologics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 50. Anges Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 51. Bluebird Bio Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 52. Jazz Pharmaceuticals Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 53. Dynavax Technologies Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 54. Biogen Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 55. Sarepta Therapeutics Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 56. Gilead Sciences Revenue Growth Rate in Viral Vectors Gene Therapy Business (2019-2024)
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
